Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTPURFN)

• DTT Name: Cyclic ADP-ribose hydrolase 1 (CD38) DTT Info
• Gene Name: CD38

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Daratumumab	DMKCIUZ	Multiple myeloma	2A83	Approved	[1]

21 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mezagitamab	DMWJXFO	Myasthenia gravis	8C6Y	Phase 2	[2]
4SCAR19 and 4SCAR38	DMZKFU7	B-cell lymphoma	2A86	Phase 1/2	[3]
Anti-CD38 CAR-T cells	DMTVXBY	Multiple myeloma	2A83	Phase 1/2	[4]
CD38 and BCMA CAR-T Cells	DMFZS8A	Multiple myeloma	2A83	Phase 1/2	[5]
CD38 CAR T cells	DMPS3I6	Multiple myeloma	2A83	Phase 1/2	[6]
CD38 CAR-T Cell	DM0USBX	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[7]
CD38-specific gene-engineered T cells	DMCH98G	Acute myeloid leukaemia	2A60	Phase 1/2	[8]
ISB 1342	DMG107N	Multiple myeloma	2A83	Phase 1/2	[9]
MOR-202	DMR8AHJ	Multiple myeloma	2A83	Phase 1/2	[10]
SAR-650984	DMD20YH	Haematological malignancy	2B33.Y	Phase 1/2	[11]
225Ac-labelled aCD38	DM3E2IY	Multiple myeloma	2A83	Phase 1	[12]
AMG 424	DMLAP8F	Multiple myeloma	2A83	Phase 1	[13]
CART-38 cells	DMKN8XD	Acute myeloid leukaemia	2A60	Phase 1	[14]
CD38 CAR-T	DMNX0V7	Multiple myeloma	2A83	Phase 1	[15]
KP1237	DMCGY7Q	Multiple myeloma	2A83	Phase 1	[16]
SAR442085	DM5UXAB	Plasma cell myeloma	2A83.1	Phase 1	[17]
SAR442257	DMXD5QP	Malignant neoplasm	2A00-2F9Z	Phase 1	[17]
SAR444559	DM4OMYQ	Inflammation	1A00-CA43.1	Phase 1	[18]
TAK-169	DMRINBJ	Multiple myeloma	2A83	Phase 1	[19]
TAK-573	DMUXAP1	Multiple myeloma	2A83	Phase 1	[20]
CAR-T cells targeting CD38	DMH5C37	Multiple myeloma	2A83	Clinical trial	[21]

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
HuMax-CD38b	DM4FIZJ	Solid tumour/cancer	2A00-2F9Z	Investigative	[22]

References

• [1] Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19.
• [2] Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects. Br J Clin Pharmacol. 2020 Jul;86(7):1314-1325.
• [3] ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
• [4] ClinicalTrials.gov (NCT03464916) Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
• [5] ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
• [6] ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
• [7] ClinicalTrials.gov (NCT03754764) A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy
• [8] ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
• [9] Clinical pipeline report, company report or official report of Ichnos Sciences.
• [10] Clinical pipeline report, company report or official report of MorphoSys.
• [11] Clinical pipeline report, company report or official report of Sanofi-Aventis.
• [12] Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
• [13] Clinical pipeline report, company report or official report of Amgen.
• [14] ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
• [15] Clinical pipeline report, company report or official report of Sorrento Therapeutics.
• [16] ClinicalTrials.gov (NCT04634435) A Phase 1 Study of Autologous Memory-like Natural Killer (NK) Cell Immunotherapy With BHV-1100 (Formerly KP1237) and IVIG Followed by Low Dose IL-2 as Early Post-Autologous Transplant Consolidation in Minimal Residual Disease Positive, Multiple Myeloma (MM) Patients in First or Second Remission. U.S.National Institutes of Health.
• [17] Clinical pipeline report, company report or official report of Sanofi.
• [18] Clinical pipeline report, company report or official report of Sanofi
• [19] Clinical pipeline report, company report or official report of Molecular Templates.
• [20] Clinical pipeline report, company report or official report of Takeda.
• [21] ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
• [22] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2766).